2024
A novel digital twin strategy to enable the translation of evidence from randomized control trials to new populations
Thangaraj P, Shankar S, Oikonomou E, Khera R. A novel digital twin strategy to enable the translation of evidence from randomized control trials to new populations. European Heart Journal 2024, 45: ehae666.3502. DOI: 10.1093/eurheartj/ehae666.3502.Peer-Reviewed Original ResearchRandomized clinical trialsPatient populationTranslation of evidenceEffect sizeNon-significant effect sizeRandomized controlled trialsCardiovascular event-free survivalSignificant effect sizeIntensive blood pressure controlEvent-free survivalSPRINT participantsSprintACCORD participantsBlood pressure controlReal-world settingsEffect estimatesControlled trialsMeasured covariatesMedical practiceTreatment effect estimatesCovariate distributionsOriginal trialsACCORD trialCardiovascular eventsClinical trials
2022
Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes.
Oikonomou EK, Suchard MA, McGuire DK, Khera R. Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes. Diabetes Care 2022, 45: 965-974. PMID: 35120199, PMCID: PMC9016734, DOI: 10.2337/dc21-1765.Peer-Reviewed Original ResearchConceptsCanagliflozin Cardiovascular Assessment StudyMajor adverse cardiovascular eventsType 2 diabetesHazard ratioSodium-glucose cotransporter 2 inhibitorsCardiovascular disease benefitAdverse cardiovascular eventsCotransporter 2 inhibitorsEffects of canagliflozinCanagliflozin dosesCanagliflozin's effectsCardiovascular eventsCardiovascular riskPatients 5Cardioprotective effectsSGLT2 inhibitorsDisease benefitBaseline variablesOriginal trialCanagliflozinType 2DiabetesPatientsRisk estimatesEffect estimates